MAOB and Parkinson disease: A group of researchers did both in vivo and in vitro experiments to examine whether safinamide (monoamine oxidase B and sodium channel blocker) has effects on microglial activation and the degeneration of dopaminergic neurons, which are closely associated with PD [37].